Open Access

Displacement affinity chromatography of protein phosphatase one (PP1) complexes

  • Greg BG Moorhead1Email author,
  • Laura Trinkle-Mulcahy2,
  • Mhairi Nimick1,
  • Veerle De Wever1,
  • David G Campbell3,
  • Robert Gourlay3,
  • Yun Wah Lam2 and
  • Angus I Lamond2
BMC Biochemistry20089:28

DOI: 10.1186/1471-2091-9-28

Received: 08 May 2008

Accepted: 10 November 2008

Published: 10 November 2008

Abstract

Background

Protein phosphatase one (PP1) is a ubiquitously expressed, highly conserved protein phosphatase that dephosphorylates target protein serine and threonine residues. PP1 is localized to its site of action by interacting with targeting or regulatory proteins, a majority of which contains a primary docking site referred to as the RVXF/W motif.

Results

We demonstrate that a peptide based on the RVXF/W motif can effectively displace PP1 bound proteins from PP1 retained on the phosphatase affinity matrix microcystin-Sepharose. Subsequent co-immunoprecipitation experiments confirmed that each identified binding protein was either a direct PP1 interactor or was in a complex that contains PP1. Our results have linked PP1 to numerous new nuclear functions and proteins, including Ki-67, Rif-1, topoisomerase IIα, several nuclear helicases, NUP153 and the TRRAP complex.

Conclusion

This modification of the microcystin-Sepharose technique offers an effective means of purifying novel PP1 regulatory subunits and associated proteins and provides a simple method to uncover a link between PP1 and additional cellular processes.

Background

The phosphorylation of proteins is one of the most prevalent covalent modifications known, affecting essentially every aspect of cellular function [1, 2]. The protein kinases and phosphatases responsible are highly conserved across species and, with few exceptions, the kinases belong to one large gene family while the phosphatase complement is more complex and can be divided into three broad groups based on protein sequence, catalytic signature and substrate preference [35]. The action of protein phosphatases is tightly controlled with cellular targeting being an important means of regulation. Most phospho-serine and threonine dephosphorylation can be attributed to the PPM family and the more diverse PPP family, which includes PP1, PP2A, PP2B, and PP4 through to PP7. PP1 is thought to not exist as a free catalytic subunit in the cell, but to reside in complexes with a large array of targeting or regulatory subunits that define its function. Numerous PP1 docking proteins have been identified, but they most likely represent only a small fraction of the total number in the cell.

The microcystins are a group of cyclic peptides that bind with remarkable specificity and affinity to the type one, 2A and several recently identified protein phosphatases of the PPP family (e.g. PP4, PP6). Microcystin covalently couples to a conserved cysteine residue of PPP family members through its methyl-dehydroalanine residue [6, 7]. Nishiwaki et al [8] first used Microcystin-Sepharose to purify PP2A. We exploited a different synthetic approach whereby the carbon-carbon double bond of methyl-dehydroalanine in microcystin couples the latter to aminoethanethiol, which is then linked to a Sepharose bead. This generates a high affinity binding matrix for the microcystin-sensitive protein phosphatases that does not covalently couple the phosphatase [6]. Microcystin-Sepharose has proved to be a powerful tool to purify these protein phosphatases and their associated regulatory subunits from a variety of tissues and cell types [912].

With only a few characterized exceptions, PP1 interacting proteins bind PP1 through their primary docking sequence called the RVXF/W motif [13]. Their molecular interaction with PP1 has been visualized via PP1-peptide and PP1 regulatory subunit structures [14, 15]. It has also emerged that additional or secondary interaction sites often play a role in binding PP1 and likely contribute to PP1 isoform specificity recognition, substrate docking and modulation of PP1 activity [13, 1520]. Based on a compilation of demonstrated RVXF/W interaction motifs [2123], the panning of a random peptide library [24], and mutagenesis and modeling studies [23] we noted preferences for particular amino acids within and adjacent to the RVXF/W motif. This led us to speculate that a PP1 interaction motif peptide, based on this comparison, could be a unique means to specifically disrupt PP1-targetting or regulatory subunit interactions [14, 25, 26]. Slight variation in the RVXF/W-motif combined with the now recognized additional, secondary PP1 interaction sites provide sufficient interaction specificity which may allow the development of drugs or peptide mimetics to abolish specific PP1 binding protein interactions in vivo. The idea of targeting protein-protein interaction domains with drugs has historically not been favored by the pharmaceutical industry yet, due to improved understanding of the underlying molecular mechanisms, it is now a concept that is growing in popularity [27, 28]. This idea has been explored with PKA anchoring proteins (AKAPs) where optimal RI and RII subunit binding peptides were derived from parent peptides and used to target PKA in vivo and displace it from its normal anchoring site [29]. In addition to in vivo targeting, disrupting PP1-regulatory subunit interactions with a peptide would be an effective means to aid in identifying proteins in PP1 complexes and thus uncover new cellular processes regulated by this protein phosphatase.

Results and Discussion

We initiated our PP1 peptide displacement study selecting RVXF/W containing peptides from the PP1 targeting subunits NIPP1 [25, 30] and ZAP (ZAP3) [31, 32]. They were synthesized and tested for their ability to displace PP1 binding proteins from complexes retained on the microcystin matrix. In brief, we isolated rat liver nuclei, extracted proteins and incubated extracts with Microcystin-Sepharose to bind the microcystin-sensitive protein phosphatases [31]. After extensive column washing, we incubated the matrix with the NIPP1 or ZAP peptides (RPKRKRKNSRVTF SEDDEII and GKKRVRW ADLE, respectively) to selectively displace proteins retained on the matrix through PP1. This implies that PP1 itself and other microcystin-sensitive phosphatase complexes should be retained on the matrix and can subsequently be eluted with the chaotrophic agent sodium thiocyanate (NaSCN), which will also displace other bound proteins [9] including some that may be retained by binding non-specifically to the Sepharose bead. Blotting for PP1 and the PP2A regulatory subunit PR65 show this to be true (Figure 1a and 1b) with no retention of these phosphatase subunits on a control matrix coupled with Tris alone. The NIPP1 peptide (RPKRKRKNSRVTF SEDDEII) readily displaced PP1 regulatory subunits (data not shown), yet we chose to continue working with the ZAP peptide (GKKRVRW ADLE, later also referred to as RVRW peptide) because it is small, readily soluble and an excellent match to the optimal PP1 binding peptide discovered through panning a random peptide library [24]. Indeed, the ZAP peptide RVRW motif and the additional C-terminal amino acids ADL and N-terminal basic amino acids (KK) were most frequently obtained in the random peptide library screen (Figure 2 in [24]). We thus predict that the ZAP sequence GKKRVRW ADLE is the most suitable, high affinity peptide that will compete and displace most other proteins docked to PP1 through variations of the RVXF/W-motif. We acknowledge that even with an 'optimal binding peptide' there are certainly other PP1 interacting proteins on the matrix that may not be displaced because of completely novel PP1 interaction sites and/or additional interaction sites outside of the RVXF/W-motif [20] that could maintain the interaction with PP1 even if the RVXF/W site is displaced. Thus, the PP1 binding partners uncovered here still most likely only represent a sub-population of the total nuclear PP1 binding partners.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2091-9-28/MediaObjects/12858_2008_Article_214_Fig1_HTML.jpg
Figure 1

A peptide based on the PP1 interaction motif RVXF/W displaces PP1 regulatory subunits from the affinity matrix microcystin-Sepharose. Proteins extracted from isolated rat liver nuclei were incubated with the affinity (MC) or control (Con) matrix (Tris coupled). Proteins were displaced with the RPKRKRKNSRVTF SEDDEII peptide (a), while in (b), elution was performed with either RPKRKRKNSRVTF SEDDEII or GKKRVRW ADLE prior to the 3 M NaSCN elution. The control matrix is only used in the panel (a) experiment while microcystin-Sepharose is used in all others. After concentration, samples were run on 10% SDS-PAGE, blotted to nitrocellulose and membranes were probed with anti-PR65 and PP1 antibodies. In panel (c) the membrane was probed with anti-ZAP, p99 or NIPP1 antibodies [31]. To test for the salt dependence of peptide displacement, columns were eluted with peptide plus or minus NaCl as indicated and samples blotted for NIPP1 (d). To determine optimal peptide concentration for displacement from the column, the protein loaded beads were divided into 3 equal parts and eluted with 0.1, 0.5 and 2 mM peptide (e). To test for the specificity of the peptide displacement, the beads were divided into 3 equal parts and eluted with either GKKRVRW ADLE, the GKKRVRW ADLE peptide with the key interacting residues changed to A (GKKRARA ADLE), or a scrambled version of the GKKRVRW ADLE peptide (KLRGEVAKDWR) and blotted for ZAP, p99 and NIPP1. Glycogen particles were isolated from rabbit skeletal muscle and PP1GM bound to the microcystin matrix followed by peptide elution first with the GKKRARA ADLE peptide, then GKKRVRW ADLE, followed by 3 M NaSCN.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2091-9-28/MediaObjects/12858_2008_Article_214_Fig2_HTML.jpg
Figure 2

Displacement affinity chromatography purification of PP1 complexes from HeLa cell nuclei. (a) A HeLa cell nuclear extract was incubated with microcystin-Sepharose, washed extensively and eluted with the GKKRARA ADLE peptide, followed by GKKRVRW ADLE peptide and finally with 3 M NaSCN. Each fraction was concentrated to an equal volume, run on 4–12% SDS-PAGE (Invitrogen) and stained with Collodial blue. Individual bands were excised, trypsin digested and identified by mass spectrometry (see Additional files 2 and 4). In (b) the same samples from panel (a) were blotted to a membrane and probed with antibodies to proteins identified by mass spectrometry. Protein names are defined in abbreviations list.

RVRW peptide eluted samples were blotted for the known nuclear PP1 binding proteins ZAP, p99 (PNUTS) and NIPP1 (Figure 1c). This revealed that these proteins were readily displaced from the matrix by the peptide with essentially no further regulatory subunit being eluted with NaSCN. A direct comparison of elution conditions with the GKKRVRW ADLE peptide showed that displacement was much more effective in a higher ionic strength buffer (Figure 1d). Having established that the GKKRVRW ADLE peptide is an excellent tool to displace PP1 regulatory subunits, we tried several peptide concentrations to optimize displacement from the matrix (Figure 1e). This demonstrated that 0.1 mM peptide was sufficient to displace ZAP and p99, but 0.5 to 2 mM peptide was needed to remove all of the more abundant and perhaps higher affinity binding NIPP1 protein. At the 2 mM peptide concentration we noted that displacement was in fact not as effective for ZAP or p99. In subsequent experiments we eluted by first incubating with 0.5 mM, then 2 mM peptide to ensure all PP1 complex proteins were displaced. To ensure the specificity of the method, we included 2 independent negative controls. Nuclear phosphatases bound to the microcystin matrix were equally divided into 3 parts and eluted with either the GKKRVRW ADLE peptide, the GKKRVRW ADLE peptide where the key PP1 interacting amino acids (V and W) were replaced by alanine (GKKRARA ADLE), or a scrambled ZAP peptide (KLRGEVAKDWR). These fractions were blotted for ZAP, p99 and NIPP1 (Figure 1f) confirming the specificity of the displacement technique.

To extend this method to PP1 complexes outside the nucleus, we isolated glycogen particles from skeletal muscle where the well characterized PP1 regulatory subunit GM resides and functions to target PP1 to glycogen [22]. As shown in Figure 1g, the peptide GKKRVRW ADLE effectively displaced GM from the microcystin-matrix. In addition, prior to the RVRW displacement, we performed an incubation with the GKKRARA ADLE peptide and, as predicted, due to the absence of the key V and W residues in the docking motif, this peptide did not displace the GM protein from the matrix which supports the idea that the peptide elution is specific for PP1 complexes. All subsequent experiments included the GKKRARA ADLE peptide elution and buffer wash step prior to GKKRVRW ADLE peptide displacement.

Having developed this methodology, we scaled it up to specifically release PP1 interacting proteins from the matrix with the aim of identifying novel, less abundant nuclear PP1 regulatory subunits and/or proteins that reside in PP1 complexes. We predict many more unrecognized PP1 regulatory subunits exist whose identification may have been masked in previous studies when all microcystin-sensitive phosphatases (especially the abundant PP2A complex) and non-specifically bound proteins were released from the matrix using NaSCN alone [31]. Furthermore, peptides may not be detected during mass spectrometry in the presence of more abundant peptides. Using an extract prepared from isolated rat liver nuclei we could show that GKKRVRW ADLE peptide displacement gave a banding pattern on SDS-PAGE that was clearly distinct from the subsequent NaSCN elution [Additional file 1]. Individual GKKRVRW ADLE eluted bands were excised from the gel and proteins identified by mass spectrometry [Additional file 2]. Many previously characterized and new potential PP1 binding proteins were identified. To validate our findings in different organisms, we then switched our attention to the human HeLa cell line. Here the GKKRARA ADLE, GKKRVRW ADLE and NaSCN column elutions again show distinct protein patterns (Fig 2a). Mass spectrometry identification of individual bands from the GKKRVRW ADLE displacement is shown in Additional file 3 and file 4. For many of the identified proteins we were able to obtain antibodies and blotting of the individual elution steps confirmed that the GKKRARA ADLE peptide did not elute any of the known or putative new PP1 interactors, supporting the idea that all of the GKKRVRW ADLE released proteins reside in PP1 complexes and that many are direct PP1 binding proteins (Figure 2b). Of note is the abundant presence of putative PP1 docking sites within the sequences of identified proteins (additional files 2 and 4). Although we predict only PP1 binding/complex proteins should elute with docking site peptide, mass spectrometry reveals that some PP1 catalytic and PP2A components did release with GKKRVRW ADLE elution, while blotting showed that the vast majority of the total pool of these subunits were retained on the matrix (Figure 2b). This is not surprising given that some complexes likely contain both PP1 and PP2A [33] and other proteins may contain more than one PP1 dock site. The lack of displacement with the GKKRARA ADLE peptide, and subsequent elution with GKKRVRW ADLE provide compelling evidence that PP1 directly docks or is in these protein complexes. To explore this further we performed immunoprecipitations with antibodies we obtained for many of these proteins and in every instance tested we could demonstrate the interaction with PP1 (Figure 3). These data again support the idea that we specifically eluted PP1 complex proteins from the matrix. One reason for using the RVRW peptide elution was to specifically displace proteins and not release any polypeptides that associate non-specifically. It is known that some proteins bind non-specifically to Sepharose beads and thus we sought to determine if the proteins discovered here were retained on Sepharose alone and eluted with the GKKRVRW ADLE peptide. Therefore, as an additional control, we passed a HeLa nuclear extract over Sepharose beads alone, washed as usual, then eluted with the GKKRARA ADLE and GKKRVRW ADLE peptides and NaSCN, as described for the microcystin-matrix. These samples were then western blotted for a selection of interactors that were previously retained on the microcystin-Sepharose and eluted with the GKKRVRW ADLE peptide (Figure 2b). When the entire GKKRARA ADLE, GKKRVRW ADLE and NaSCN fractions were individually concentrated and run on a single lane and blotted versus 1/175 of the input (which gave a strong western signal) we did weakly detect several of these proteins in the NaSCN elution (as expected), but only noted signals for filamin A and PSF in the GKKRVRW ADLE peptide elution (data not shown). Given that this is in comparison to 1/175 of the input, this represents a very minor background displacement and functions to remind us that, as in any exploratory work, additional experiments are needed to confirm true interactors. Interestingly, PSF has previously been defined as a PP1 docking protein [34].
https://static-content.springer.com/image/art%3A10.1186%2F1471-2091-9-28/MediaObjects/12858_2008_Article_214_Fig3_HTML.jpg
Figure 3

Co-immunprecipitation of PP1 with HeLa nuclear PP1 binding and complex proteins. Antibodies were obtained for the proteins shown and immunoprecipitations performed. Immunoprecipitated proteins were run on SDS-PAGE, transferred to a membrane and probed with the same antibodies as indicated plus a pan PP1 antibody to determine if PP1 co-immunoprecipitates. The immunoprecipitating antibody is shown on the left and in all cases a pre-immune serum control was done in parallel (PIS). The blotting antibody it indicated on the right.

It is notable from the mass spectrometry data that we identified many nuclear processes or complexes not previously linked to PP1. For instance, we found numerous TIP60 (TRRAP) complex proteins [35]. Immunoprecipitation of the TIP60 components TRRAP or p400 (Domino) were able to bring down PP1, confirming that PP1 is a previously unrecognized component of this complex. Putative interacting proteins or complexes identified here will need to be confirmed by co-immunoprecipitation experiments or other methods, and then ultimately all complexes, including the TRRAP complex, will need to be studied to define the role of PP1 binding to that protein or group of proteins.

A comparison of the proteins eluted and identified from rat and human nuclei reveals that most of the proteins are the same (although the number of rat proteins is greater), but several differences are apparent. First, some differences are not surprising given that the HeLa cell line expresses numerous proteins that differ from the rat liver cell proteome. In addition, there are quite a number of proteins in the rat samples that appear in multiple bands excised from the gel, but this only occurs a few times in the HeLa bands. This is likely due to the fact that preparation of the rat nuclei from liver tissue is more time consuming and thus we expect increased proteolysis of proteins and therefore many more hits of the same protein in bands of many masses. Comparing rat liver versus cells grown in culture also means that we started with much more protein from the rat preparation and this certainly contributed to the identification of more lower abundance proteins.

To date several approaches have been used to define the PP1-interactome of the cell, including total (NaSCN) elution from microcystin-Sepharose followed by overlay analysis, SILAC mass spectrometry based PP1 binding partner investigation and most recently an antibody array approach for selected putative targets [11, 31, 36, 37]. Any methodology has its limitations; our work certainly represents a subgroup of the total PP1 targeted protein/complexes of the nucleus for reasons discussed above and because our nuclear extraction procedure likely only released some fraction of the total PP1 complexes. It is clear that many more PP1 binding partners exist than originally thought and it will be the combination of multiple approaches that will ultimately define the plethora of roles for PP1 in the nucleus and other cellular compartments.

Conclusion

We have developed a method to specifically elute proteins that reside in PP1 complexes or bind directly to PP1 after retention on the affinity matrix microcystin-Sepharose. This approach should be valuable to isolate new PP1 binding proteins and to link PP1 function to as yet unrecognized PP1 regulated cellular processes across a broad range of tissues, cell types and organisms. This technique also lends further credibility to the notion that it could be possible to develop peptides as tools for the specific disruption of protein protein interactions with potential usage for therapeutic purposes.

Methods

HeLa nuclear extracts

For HeLa cells, nuclei were isolated and extracted from ~1 × 109 cells grown in spinner flasks using the method outlined at http://www.lamondlab.com. Sonicated, extracted nuclei were made to 0.42 M NaCl, mixed end-over-end for 10 min. at 4°C and clarified by centrifugation at 10,000 g for 10 min. This clarified extract was then mixed with the microcystin matrix.

Affinity displacement chromatography

Microcystin-Sepharose was prepared as described [7, 9]. Control matrix was prepared by coupling to Tris instead of aminoethanethiol-microcystin. In a typical nuclear preparation, the livers of 10 rats were homogenized, nuclei isolated and proteins extracted [31]. Nuclear proteins were incubated end over end with 1 mL of microcystin-Sepharose or control matrix for 1 h at 4°C and then washed in a column with 250 mL of buffer A (25 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 1 mM benzamidine, 0.1 mM PMSF, 0.1% β-ME) plus 300 mM NaCl. All peptides were dissolved in buffer A plus 300 mM NaCl and the pH adjusted to 7.5 with 1 N NaOH by spotting on pH paper. The matrix (1 mL) was first incubated with 2 mL 0.5 mM peptide for 30 min. and the eluted protein collected with the addition of 2 mL buffer A plus 300 mM NaCl. The matrix was then incubated with 2 mL 2 mM peptide for 30 min. and the eluted protein collected with the addition of 5 mL buffer A plus 300 mM NaCl. After washing with an additional 30 mL of buffer A plus 300 mM NaCl, the column was eluted with 3 M sodium isothiocyanate in buffer A [9]. The peptides used were RPKRKRKNSRVTF SEDDEII (from human NIPP1), GKKRVRW ADLE (from human ZAP), GKKRARA ADLE (from human ZAP with alanine substitutions for V and W) and KLRGEVAKDWR (scrambled GKKRVRW ADLE). The 0.5 and 2 mM peptide elutions were pooled and immediately concentrated in a centriprep 10, then centricon 10 to 40 μL and boiled in 5× SDS-cocktail. The NaSCN elution was dialyzed extensively and concentrated to 40 μL as described for the peptide elutions and boiled in 5× SDS-cocktail. Samples were run on 10% SDS-PAGE or in some cases on 4–12% gradient gels (Invitrogen).

Isolation of rabbit skeletal muscle glycogen particles and chromatography on MC-Sepharose

Skeletal muscle from the back and hind legs of one rabbit was removed, placed on ice, minced and homogenized with 2.5 L/kg homogenization buffer (2 mM EDTA, 2 mM EGTA, 0.1% B-ME, 1 mM benzamidine, 0.1 mM PMSF) in a blender and centrifuged in a Beckman J6 at 4200 rpm for 30 min. at 4°C. The supernatant was decanted through glass wool in a funnel and the pH of the solution lowered to 6.1 with 1 M acetic acid. After 15 min on ice, glycogen was pelleted by centrifugation at 4200 rpm for 30 min. at 4°C. The glycogen pellet was resuspend in 100 mL of the following buffer (50 mM Tris-HCl pH 7, 2 mM EGTA, 5% V/V glycerol, 4 μg/mL leupeptin, 1 mM benzamidine, 0.1 mM PMSF, and 0.1% β-ME.) and loaded on a 1 mL microcystin-Sepharose column equilibrated with microcystin-Sepharose buffer A. After incubation for 1.5 hour with an end-over-end machine, then washing with microcystin-Sepharose buffer A plus 0.3 M NaCl (200 column volumes or until no protein comes off in a Bradford assay) the matrix was eluted with peptides and NaSCN as described above.

Mass spectrometry

For protein identification by mass spectrometry bands were excised from colloidal blue stained gels, digested with trypsin and LC-MS/MS was performed as in Ulke-Lemée et al [32]. Peak lists were searched with Mudpit scoring using Mascot version (v2.2). We used the criteria of 2 matching peptides for a positive identification.

Immunoprecipitations

Antibodies to proteins or an equivalent amount of pre-immune serum purified IgG were coupled to Protein A-Sepharose (GE Healthcare) and incubated with HeLa cell extracts (from 4 × 10 cm plates) end over end for 2 h at 4°C. After sedimentation, IP pellets were washed 2× with PBS, 2× with PBS plus 0.05% NP-40 and 150 mM NaCl and 2 more times in PBS, before boiling in SDS-cocktail. In all cases, antibody and pre-immune serum IPs were incubated with identical amounts of protein, washed in parallel and eluted with an equal volume of cocktail to allow direct comparison on western blots.

Antibodies were kindly provided by individuals or purchased as indicated in brackets. PP1, NIPP1, p99 (PNUTS), SAP155, ZAP and their use are detailed in Tran et al [31]. Other antibodies were PR65 (B. Hemmings), GM and M110 (P. Cohen), DPK-1 (SP Lees-Miller), NUP153 (M. Lohka), DDX5 (F. Fuller-Pace), RAVER-1 (B. Jockusch), TOPOIIα (E. Kurz), TRRAP, Envoplakin, HDAC6, PSF (Santa Cruz), Ki-67, p53bp2 [ASPP2], p54nrb/nono (BD Biosciences), Rif-1, p84 [Thoc1], P400 (Abcam), Filamin-A (Chemicon), NUMA-1 (Nova Biologicals), DDX18, DDX17 [DNA helicaseA] (Bethyl Lab), HDAC1 (Cell Signaling), PP2A-C (Transduction Labs).

Abbreviations

DPK1: 

DNA-dependent protein kinase

TRRAP: 

transformation/transcription domain-associated protein

RIF1: 

Rap1-interacting factor 1

NUMA-1: 

nuclear mitotic apparatus protein 1

TOPOIIα: 

topoisomerase IIα

SAP155: 

spliceosome-associated protein 155

NUP153: 

nucleoporin 153

M110/MYPT1: 

myosin targeting subunit 110

p53bp2: 

p53 binding protein 2

PSF: 

PTB-associated splicing factor

RAVER1: 

ribonucleoprotein: PTB-binding 1

PR65: 

PP2A scaffolding or A subunit

p400/Domino: 

E1A-binding protein p400

ASPP: 

apoptosis stimulating proteins of p53

NaSCN: 

sodium isothiocyanate

HDAC: 

histone deacetylase

DDX: 

DEAD box family of RNA helicases

PP1: 

protein phosphatase one

PP2A: 

protein phosphatase 2A

LCP1: 

epidermal Langerhans cell protein

KPI-2: 

Kinase/Phosphatase/Inhibitor-2

NIPP: 

nuclear inhibitor of protein phosphatase-1: ZAP (ZAP3): YLPM-motif contain PP1 interactor

p99: 

PP1 interactor (also PNUTS)

GM

skeletal muscle glycogen binding PP1 interactor

MC: 

microcystin

p84/Thoc1: 

THO complex 1

p54nrb/nono: 

54 kDa nuclear RNA binding protein

NUP50: 

nucleoporin 50

TIP49a/RUVBL2: 

TBP-interacting protein 49/RuvB-like 2

PP4: 

protein phosphatase four

Repo-Man: 

recruits PP1 onto mitotic chromatin at anaphase

MBS85: 

myosin-binding subunit of 85 kDa

LRR-Ri: 

Leucine-rich repeats (LRRs): ribonuclease inhibitor

GRP78: 

Glucose-Regulated Protein of 78-kDa.

Declarations

Acknowledgements

This work was supported by the Natural Sciences and Engineering Research Council of Canada and the Alberta Cancer Board.

Authors’ Affiliations

(1)
Department of Biological Sciences, University of Calgary
(2)
Wellcome Trust Biocentre, MSI/WTB Complex, University of Dundee
(3)
MRC Protein Phosphorylation Unit, School of Life Sciences, University of Dundee

References

  1. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M: Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks. Cell. 2006, 127 (3): 635-648. 10.1016/j.cell.2006.09.026.View ArticlePubMedGoogle Scholar
  2. Cohen P: The origins of protein phosphorylation. Nat Cell Biol. 2002, 4 (5): E127-130. 10.1038/ncb0502-e127.View ArticlePubMedGoogle Scholar
  3. Moorhead GB, Trinkle-Mulcahy L, Ulke-Lemée A: Emerging roles of nuclear protein phosphatases. Nat Rev Mol Cell Biol. 2007, 8 (3): 234-244. 10.1038/nrm2126.View ArticlePubMedGoogle Scholar
  4. Tonks NK: Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006, 7 (11): 833-846. 10.1038/nrm2039.View ArticlePubMedGoogle Scholar
  5. Kerk D, Templeton G, Moorhead GB: Evolutionary radiation pattern of novel protein phosphatases revealed by analysis of protein data from the completely sequenced genomes of humans, green algae, and higher plants. Plant Physiol. 2008, 146 (2): 351-367. 10.1104/pp.107.111393.PubMed CentralView ArticlePubMedGoogle Scholar
  6. MacKintosh RW, Dalby KN, Campbell DG, Cohen PT, Cohen P, MacKintosh C: The cyanobacterial toxin microcystin binds covalently to cysteine-273 on protein phosphatase 1. FEBS Lett. 1995, 371 (3): 236-240. 10.1016/0014-5793(95)00888-G.View ArticlePubMedGoogle Scholar
  7. Moorhead GB, Haystead TA, MacKintosh C: Synthesis and use of the protein phosphatase affinity matrices microcystin-sepharose and microcystin-biotin-sepharose. Methods Mol Biol. 2007, 365: 39-45.PubMedGoogle Scholar
  8. Nishiwaki S, Fujiki H, Suganuma M, Nishiwaki-Matsushima R, Sugimura T: Rapid purification of protein phosphatase 2A from mouse brain by microcystin-affinity chromatography. FEBS Lett. 1991, 279 (1): 115-118. 10.1016/0014-5793(91)80264-4.View ArticlePubMedGoogle Scholar
  9. Moorhead G, MacKintosh RW, Morrice N, Gallagher T, MacKintosh C: Purification of type 1 protein (serine/threonine) phosphatases by microcystin-Sepharose affinity chromatography. FEBS Lett. 1994, 356 (1): 46-50. 10.1016/0014-5793(94)01232-6.View ArticlePubMedGoogle Scholar
  10. Moorhead G, MacKintosh C, Morrice N, Cohen P: Purification of the hepatic glycogen-associated form of protein phosphatase-1 by microcystin-Sepharose affinity chromatography. FEBS Lett. 1995, 362 (2): 101-105. 10.1016/0014-5793(95)00197-H.View ArticlePubMedGoogle Scholar
  11. Campos M, Fadden P, Alms G, Qian Z, Haystead TA: Identification of protein phosphatase-1-binding proteins by microcystin-biotin affinity chromatography. J Biol Chem. 1996, 271 (45): 28478-28484. 10.1074/jbc.271.45.28478.View ArticlePubMedGoogle Scholar
  12. Brush MH, Guardiola A, Connor JH, Yao TP, Shenolikar S: Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem. 2004, 279 (9): 7685-7691. 10.1074/jbc.M310997200.View ArticlePubMedGoogle Scholar
  13. Bollen M: Combinatorial control of protein phosphatase-1. Trends Biochem Sci. 2001, 26 (7): 426-431. 10.1016/S0968-0004(01)01836-9.View ArticlePubMedGoogle Scholar
  14. Egloff MP, Johnson DF, Moorhead G, Cohen PT, Cohen P, Barford D: Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. Embo J. 1997, 16 (8): 1876-1887. 10.1093/emboj/16.8.1876.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Terrak M, Kerff F, Langsetmo K, Tao T, Dominguez R: Structural basis of protein phosphatase 1 regulation. Nature. 2004, 429 (6993): 780-784. 10.1038/nature02582.View ArticlePubMedGoogle Scholar
  16. Neduva V, Linding R, Su-Angrand I, Stark A, de Masi F, Gibson TJ, Lewis J, Serrano L, Russell RB: Systematic discovery of new recognition peptides mediating protein interaction networks. PLoS Biol. 2005, 3 (12): e405-10.1371/journal.pbio.0030405.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Hurley TD, Yang J, Zhang L, Goodwin KD, Zou Q, Cortese M, Dunker AK, DePaoli-Roach AA: Structural basis for regulation of protein phosphatase 1 by inhibitor-2. J Biol Chem. 2007, 282 (39): 28874-28883. 10.1074/jbc.M703472200.View ArticlePubMedGoogle Scholar
  18. Ayllon V, Cayla X, Garcia A, Fleischer A, Rebollo A: The anti-apoptotic molecules Bcl-xL and Bcl-w target protein phosphatase 1alpha to Bad. Eur J Immunol. 2002, 32 (7): 1847-1855. 10.1002/1521-4141(200207)32:7<1847::AID-IMMU1847>3.0.CO;2-7.View ArticlePubMedGoogle Scholar
  19. Chang JS, Henry K, Wolf BL, Geli M, Lemmon SK: Protein phosphatase-1 binding to scd5p is important for regulation of actin organization and endocytosis in yeast. J Biol Chem. 2002, 277 (50): 48002-48008. 10.1074/jbc.M208471200.View ArticlePubMedGoogle Scholar
  20. Carmody LCBAn, Bass MA, Colbran RJ: Selective targeting of the gamma1 isoform of protein phosphatase 1 to F-actin in intact cells requires multiple domains in spinophilin and neurabin. FASEB J. 2008, 6 (6): 1660-1671. 10.1096/fj.07-092841.View ArticleGoogle Scholar
  21. Ceulemans H, Bollen M: Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol Rev. 2004, 84 (1): 1-39. 10.1152/physrev.00013.2003.View ArticlePubMedGoogle Scholar
  22. Cohen PT: Protein phosphatase 1 – targeted in many directions. J Cell Sci. 2002, 115 (Pt 2): 241-256.PubMedGoogle Scholar
  23. Meiselbach H, Sticht H, Enz R: Structural analysis of the protein phosphatase 1 docking motif: molecular description of binding specificities identifies interacting proteins. Chem Biol. 2006, 13 (1): 49-59. 10.1016/j.chembiol.2005.10.009.View ArticlePubMedGoogle Scholar
  24. Zhao S, Lee EY: A protein phosphatase-1-binding motif identified by the panning of a random peptide display library. J Biol Chem. 1997, 272 (45): 28368-28372. 10.1074/jbc.272.45.28368.View ArticlePubMedGoogle Scholar
  25. Beullens M, Van Eynde A, Vulsteke V, Connor J, Shenolikar S, Stalmans W, Bollen M: Molecular determinants of nuclear protein phosphatase-1 regulation by NIPP-1. J Biol Chem. 1999, 274 (20): 14053-14061. 10.1074/jbc.274.20.14053.View ArticlePubMedGoogle Scholar
  26. Johnson DF, Moorhead G, Caudwell FB, Cohen P, Chen YH, Chen MX, Cohen PT: Identification of protein-phosphatase-1-binding domains on the glycogen and myofibrillar targetting subunits. Eur J Biochem. 1996, 239 (2): 317-325. 10.1111/j.1432-1033.1996.0317u.x.View ArticlePubMedGoogle Scholar
  27. Piljic A, Schultz C: Simultaneous recording of multiple cellular events by FRET. ACS Chem Biol. 2008, 3 (3): 156-160. 10.1021/cb700247q.View ArticlePubMedGoogle Scholar
  28. Guergnon J, Dessauge F, Dominguez V, Viallet J, Bonnefoy S, Yuste VJ, Mercereau-Puijalon O, Cayla X, Rebollo A, Susin SA, et al.: Use of penetrating peptides interacting with PP1/PP2A proteins as a general approach for a drug phosphatase technology. Mol Pharmacol. 2006, 69 (4): 1115-1124. 10.1124/mol.105.019364.View ArticlePubMedGoogle Scholar
  29. Alto NM, Soderling SH, Hoshi N, Langeberg LK, Fayos R, Jennings PA, Scott JD: Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring. Proc Natl Acad Sci USA. 2003, 100 (8): 4445-4450. 10.1073/pnas.0330734100.PubMed CentralView ArticlePubMedGoogle Scholar
  30. Trinkle-Mulcahy L, Ajuh P, Prescott A, Claverie-Martin F, Cohen S, Lamond AI, Cohen P: Nuclear organisation of NIPP1, a regulatory subunit of protein phosphatase 1 that associates with pre-mRNA splicing factors. J Cell Sci. 1999, 112 (Pt 2): 157-168.PubMedGoogle Scholar
  31. Tran HT, Ulke A, Morrice N, Johannes CJ, Moorhead GB: Proteomic characterization of protein phosphatase complexes of the mammalian nucleus. Mol Cell Proteomics. 2004, 3 (3): 257-265. 10.1074/mcp.M300115-MCP200.View ArticlePubMedGoogle Scholar
  32. Ulke-Lemee A, Trinkle-Mulcahy L, Chaulk S, Bernstein NK, Morrice N, Glover M, Lamond AI, Moorhead GB: The nuclear PP1 interacting protein ZAP3 (ZAP) is a putative nucleoside kinase that complexes with SAM68, CIA, NF110/45, and HNRNP-G. Biochim Biophys Acta. 2007, 1774 (10): 1339-1350.View ArticlePubMedGoogle Scholar
  33. Shi Y, Reddy B, Manley JL: PP1/PP2A phosphatases are required for the second step of Pre-mRNA splicing and target specific snRNP proteins. Mol Cell. 2006, 23 (6): 819-829. 10.1016/j.molcel.2006.07.022.View ArticlePubMedGoogle Scholar
  34. Hirano K, Erdödi F, Patton JG, Hartshorne DJ: Interaction of protein phosphatase type 1 with a splicing factor. FEBS Letters. 1996, 389 (2): 191-10.1016/0014-5793(96)00577-7.View ArticlePubMedGoogle Scholar
  35. Lee KK, Workman JL: Histone acetyltransferase complexes: one size doesn't fit all. Nat Rev Mol Cell Biol. 2007, 8 (4): 284-295. 10.1038/nrm2145.View ArticlePubMedGoogle Scholar
  36. Flores-Delgado G, Liu CW, Sposto R, Berndt N: A limited screen for protein interactions reveals new roles for protein phosphatase 1 in cell cycle control and apoptosis. J Proteome Res. 2007, 6 (3): 1165-1175. 10.1021/pr060504h.View ArticlePubMedGoogle Scholar
  37. Trinkle-Mulcahy L, Andersen J, Lam YW, Moorhead G, Mann M, Lamond AI: Repo-Man recruits PP1 gamma to chromatin and is essential for cell viability. J Cell Biol. 2006, 172 (5): 679-692. 10.1083/jcb.200508154.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Moorhead et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.